Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 25, 2012
Grant Date -
Aug 4, 2011
app pub date -
Mar 28, 2011
filing date -
Sep 11, 2006
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully